Radical Pharmaco-Chemistry team (PCR)

Axis 2 aims at developping new molecules and at investigating their interactions with biological systems. To comply with therapeutic issues, this interdisciplinary axis relies on organic chemistry and biology.

To develop new anti-infective agents, our work focus on the synthesis of original heterocyclic molecules endowed with an anti-infective activity (anti-parasitic, anti-bacterial or anti-viral). These topics aim at identifying new molecular mechanisms enabling to overcome resistances developed by infective agents. In parallel, other topics focus on finding new antiproliferative agents. In a drugability approach, physico-chemical properties, structure-activity relationships and pharmacokinetic parameters of prepared compounds are investigated according to a Hit-to-Lead approach to realize in vivo tests on (infected) animal models. Our laboratory is member of the national Chemical Library of CNRS making the compounds issued from our work available to the scientific community.

Local, national and international collaborations strenghthen our group, as well as fundings from various agencies (Agence Nationale de la Recherche, Fondation pour la Recherche Médicale, Partenariats Hubert Curien, Hôpitaux Universitaires de Marseille AP-HM, …).

Reviews: a) J. Broggi, T. Terme, P. Vanelle, Angew. Chem. Int. Ed. 2014, 53, 384-413. b) S. Zhou, H. Farwaha, J. A. Murphy, Chimia 2012, 66, 418-424. c) J. A. Murphy, J. Org. Chem. 2014, 79, 3731-3746. d) E. Doni, J. A. Murphy, Chem. Commun. 2014, 50, 6073-6087.